Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial (Q34310960)

1 August 2017

title

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial (English)

1 reference

acute decompensated heart failure

1 August 2017

0 references

0 references

1 reference

Beth A Davison

3

0 references

Peter S. Pang

Peter S Pang

16

0 references

Gad Cotter

Gad Cotter

2

0 references

Marco Metra

Marco Metra

24

0 references

Piotr Ponikowski

Piotr Ponikowski

7

0 references

Liliana Grinfeld

12

Liliana R Grinfeld

1 reference

1 August 2017

5

Gerasimos Filippatos

1 reference

1 August 2017

4

G Michael Felker

1 reference

1 August 2017

1

John R Teerlink

1 reference

1 August 2017

9

Adriaan A Voors

1 reference

1 August 2017

6

Barry H Greenberg

1 reference

1 August 2017

18

Sam L Teichman

1 reference

1 August 2017

8

Elaine Unemori

1 reference

1 August 2017

10

Kirkwood F Adams

1 reference

Alexandra Maria Dorobanțu

1 August 2017

11

Maria I Dorobantu

1 reference

1 August 2017

13

Guillaume Jondeau

1 reference

1 August 2017

14

Alon Marmor

1 reference

1 August 2017

19

Angelo Trapani

1 reference

1 August 2017

21

Rajnish Saini

1 reference

1 August 2017

22

Christoph Schumacher

1 reference

1 August 2017

Josep Masip

15

1 reference

1 August 2017

Karl Werdan

17

1 reference

1 August 2017

Christopher A Bush

20

1 reference

1 August 2017

Thomas M Severin

23

1 reference

1 August 2017

RELAXin in Acute Heart Failure (RELAX-AHF) Investigators

25

1 reference

1 August 2017

language of work or name

English

0 references

publication date

7 November 2012

1 reference

1 August 2017

1 reference

1 August 2017

volume

381

1 reference

1 August 2017

issue

9860

1 reference

1 August 2017

page(s)

29-39

1 reference

Heart disease and stroke statistics--2012 update: a report from the American Heart Association

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

1 reference

7 January 2021

The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Effect of nesiritide in patients with acute decompensated heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Acute heart failure syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Fluid overload in acute heart failure--re-distribution and other mechanisms beyond fluid accumulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Maternal vasodilation in pregnancy: the emerging role of relaxin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Relaxin: review of biology and potential role in treating heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Design of the RELAXin in acute heart failure study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

A sharper Bonferroni procedure for multiple tests of significance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Diuretic strategies in patients with acute decompensated heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Dyspnea and pain share emotion-related brain network

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Measuring the dyspnea of decompensated heart failure with a visual analog scale: how much improvement is meaningful?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Early worsening heart failure in patients admitted for acute heart failure: time course, hemodynamic predictors, and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Predicting the risk of unplanned readmission or death within 30 days of discharge after a heart failure hospitalization.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Divergent trends in survival and readmission following a hospitalization for heart failure in the Veterans Affairs health care system 2002 to 2006.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

The role of the kidney in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Effects of the Adenosine A1 Receptor Antagonist Rolofylline on Renal Function in Patients With Acute Heart Failure and Renal Dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Worsening renal function and prognosis in heart failure: systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

The relationship between transient and persistent worsening renal function and mortality in patients with acute decompensated heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961855-8

7 January 2021

10.1016/S0140-6736(12)61855-8

Identifiers

DOI

1 reference

1 August 2017

1 reference